Bio-Rad Laboratories (BIO-B) Capital Expenditures (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of Capital Expenditures data on file, last reported at $30.0 million in Q1 2026.

• Quarterly Capital Expenditures fell 12.79% year-over-year to $30.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $153.2 million (down 4.13% YoY) and the FY2025 annual result came in at $157.6 million, down 4.83% from the prior year.
• Capital Expenditures eased to $30.0 million in Q1 2026 per BIO-B's latest filing, from $45.8 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $45.8 million in Q4 2025 and bottomed at $17.3 million in Q2 2022.
• The 5-year median for Capital Expenditures is $35.7 million (2023), against an average of $36.6 million.
• The widest annual swing landed in 2022, when Capital Expenditures slumped 38.04%; it then surged 99.83% in 2023.
• Tracing BIO-B's Capital Expenditures over 5 years: stood at $34.8 million in 2022, then rose by 21.41% to $42.3 million in 2023, then advanced by 1.5% to $42.9 million in 2024, then increased by 6.76% to $45.8 million in 2025, then tumbled by 34.5% to $30.0 million in 2026.
• Per Business Quant, the three latest BIO-B Capital Expenditures figures stand at $30.0 million (Q1 2026), $45.8 million (Q4 2025), and $31.7 million (Q3 2025).

Peer Comparison